# A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease

> **NCT06310967** · PHASE1,PHASE2 · RECRUITING · sponsor: **Intelligem Therapeutics Australia Pty Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Hyperuricemia
- Hypouricemia, Renal

## Interventions

- **DRUG:** IG3018
- **OTHER:** Placebo matching IG3018

## Key facts

- **NCT ID:** NCT06310967
- **Lead sponsor:** Intelligem Therapeutics Australia Pty Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-12
- **Primary completion:** 2026-07
- **Final completion:** 2027-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06310967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06310967, "A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06310967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*